---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004607"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:30:59.495950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System

## Summary
- Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).
- Net loss $0.1M ($0.01/sh); adjusted net income $2.5M ($0.17/sh); adjusted EBITDA $6.3M.
- Full market release of Integrity Implant System (HA scaffold) in July; >300 cases by >60 surgeons.
- Guidance: FY2024 revenue $168-$173M (1-4% growth); adjusted EBITDA towards lower end of $25-$30M.
- New $40M share repurchase program; $15M under 10b5-1 plan initiated May 2024.

## SEC filing metadata
- accession: 0001171843-24-004607
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/0001171843-24-004607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/f8k_080824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004607
- JSON: https://secwatch.observer/filing/0001171843-24-004607.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.